Keyphrases
Clinical Utility
100%
Cell-free DNA (cfDNA)
100%
DNA mutation
100%
Anaplastic Thyroid Cancer
100%
Next-generation Sequencing
30%
Tumor Tissue
20%
Tumor Protein p53 (TP53)
20%
Gene mutation
20%
Overall Survival
20%
Treatment Selection
20%
Concordance Rate
20%
PIK3CA
20%
BRAF Inhibitor (BRAFi)
20%
University of Texas
10%
Early Diagnosis
10%
Tumor
10%
MD Anderson Cancer Center
10%
Peripheral Blood
10%
Treatment Modalities
10%
Mutated Genes
10%
Prognostic Significance
10%
Blood Draw
10%
Disease Control
10%
Turnaround Time
10%
Early Treatment
10%
Rapid Diagnosis
10%
Molecular Profile
10%
Cytotoxic Chemotherapy
10%
Rapid Treatment
10%
PIK3CA mutation
10%
BRAF V600E
10%
Mutation Testing
10%
January 2015
10%
Tumor mutation Burden
10%
Cell-free DNA Screening
10%
Treatment-naïve
10%
Timely Information
10%
Cell-free DNA Analysis
10%
Guardant360
10%
Mutation Profiling
10%
Aggressive Thyroid Cancer
10%
Medicine and Dentistry
Cell-Free DNA
100%
DNA Mutation
100%
Anaplastic Thyroid Carcinoma
100%
Neoplasm
25%
Next Generation Sequencing
25%
Gene Mutation
16%
Overall Survival
16%
Malignant Neoplasm
8%
Early Diagnosis
8%
Thyroid Cancer
8%
Cytotoxic Chemotherapy
8%
Cell-Free DNA Testing
8%
Tumor
8%
Diseases
8%
Treatment Modality
8%
Biochemistry, Genetics and Molecular Biology
Next Generation Sequencing
100%
DNA Mutation
100%
Gene Mutation
66%
Overall Survival
66%
DNA Analysis
33%
Turnaround Time
33%
Mutated Genes
33%
Pharmacology, Toxicology and Pharmaceutical Science
Anaplastic Thyroid Carcinoma
100%
Neoplasm
33%
Overall Survival
22%
Malignant Neoplasm
11%
Thyroid Cancer
11%
Cytotoxic Chemotherapy
11%
Diseases
11%